The study also emphasized the significance of LFA-1 in the success of immunotherapy, showing that elevated serum GDF-15 levels in cancer patients were linked to poor outcomes following PD-1 therapy, and that inhibiting GDF-15 improved T cell recruitment and enhanced therapeutic efficacy (103). This evidence concerns the gene ITGB2 and cancer.